December 2nd, 2017
Radnor Valley Country Club (555 Sproul Road, Villanova, PA 19085)
Breakthrough Cell and Gene Therapy (CGT) Approved or on the Brink of Being Approved in 2018
Luxturna (Spark), the world’s 1st adeno-associated viral (AAV) vector gene therapy to correct a specific genetic mutation that causes inherited retinal diseases (IRDs).
Federico Mingozzi, Ph.D., Chief Scientific Officer, Spark Therapeutics
Strimvelis (GSK), the world’s 1st Hematopoietic Stem Cell Gene Therapy (HSC-GT) for adenosine deaminase deficiency (ADA-SCID).
Joseph Tarnowski, Ph.D., Senior Vice President, Cell and Gene Therapy, GlaxoSmithKline
Promising Technologies That Can Advance Future CGT Therapies
In vivo reprogramming for brain repair, a gene therapy technology that may have broad applications in neural repair after Alzheimer’s disease, Parkinson disease and glioma.
Gong Chen, Ph.D., Professor, Verne M. Willaman Chair in Life Sciences, Penn State University
Using CRISPR/CAS9 to generate universal T cells and improve adoptive immunotherapy against solid tumors.
Yangbing Zhao, M.D., Ph.D., Director, T Cell Engineering Lab (TCEL), Adjunct Associate Professor, University of Pennsylvania
First in man CAR strategies with expanded applicability, targeting hematological cancers, non-hematological cancers and autoimmune disorders.
Wyle Solomon, M.B.A., Chief Executive Officer, iCell Gene Therapeutics
Register before Nov. 12th to save $20+! Lunch will be provided.